Contact Us

Evista
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

   * Phone 

Cell Phone 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Evista


AddThis Social Bookmark Button

Evista Side Effects May Be Linked To Stroke Lawsuits

Evista | Lawsuits, Lawyers | Side Effects: Strokes, Cardiovascular Disease

On May 18, 2006, Health Canada and Lilly Canada issued a new safety warning for the drug Evista concerning an increased risk of death due to stroke in postmenopausal women who are at increased risk of cardiovascular disease. This risk was discovered during the RUTH clinical trial which examined the use for Evista for cardiovascular disease. Evista was approved by the FDA on November 24, 1998 for the treatment and prevention of osteoporosis in postmenopausal women.

RUTH (Raloxifene Use for The Heart) Study Revealed Risk of Stroke

The RUTH (Raloxifene Use for The Heart) trial was an extensive placebo study that examined whether a 60 mg daily dose of Evista (Generic: raloxifene hydrochloride) would cut the danger of coronary events and the risk of invasive breast cancer in postmenopausal women who already had heart disease or were at an elevated risk for a coronary episode. The study was made up of more than 10,000 women (average age: 67 years) from 26 countries who were trailed for up to seven years. Every woman enrolled in RUTH had known heart disease or were at high risk for a coronary event. The trial found an increase in death as a result of stroke for Evista compared to the placebo. The rate of stroke mortality was 1.5 per 1,000 women per year for placebo versus 2.2 per 1,000 women per year for Evista.

Legal Help for Evista Users

If you or a loved one took Evista and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or call us at 1-800-LAW-INFO (1-800-529-4636).

EvistaRSS Feed

Raloxifene averts breast cancer, at a risk

Jul 13, 2006 | AP
Women with heart disease or a high risk for it would trade one set of odds for another if they took the drug raloxifene to try to prevent breast cancer, a new study suggests. The drug helped prevent cancer, but raised the risk of blood clots and fatal strokes. It also didn't lower the risk of death, hospitalization or heart attack, as some had hoped it would. Doctors have been testing this drug as an alternative to tamoxifen for preventing breast cancer and as a way to lower heart disease...
Raloxifene averts breast cancer, at a risk »

Drug increases risk of stroke death for some women

May 26, 2006 | The Toronto Star
Post-menopausal women taking a popular osteoporosis drug are at increased danger of dying from a stroke if they have heart disease or are at high risk of a heart attack, Health Canada warns. In a large-scale trial of 10,000 post-menopausal women with heart problems in 26 countries, the drug raloxifene, marketed as Evista, increased the risk of stroke death from 1.5 per thousand women to 2.2, it said yesterday. The drug received widespread publicity last month after a second trial found that...
Drug increases risk of stroke death for some women »

Association of Evista (raloxifene hydrochloride) with Increased Risk of Mortality Due to Stroke in Postmenopausal Women at Increased Risk for Cardiovascular Disease: Preliminary Results from the RUTH Trial

May 18, 2006 | Health Canada
Eli Lilly Canada Inc., following discussions with Health Canada, would like to inform you of important new safety information regarding Evista (raloxifene hydrochloride) resulting from the Raloxifene Use for The Heart (RUTH) trial.The RUTH trial, a large-scale placebo-controlled study, investigated whether a 60 mg daily dose of raloxifene hydrochloride would reduce the risk of coronary events and the risk of invasive breast cancer in postmenopausal women with known heart disease or at high risk...
Association of Evista (raloxifene hydrochloride) with Increased Risk of Mortality Due to Stroke in Postmenopausal Women at Increased Risk for Cardiovascular Disease: Preliminary Results from the RUTH Trial »

More Evista News